A controlled trial with ORG 2766, an ACTH-(4–9) analog, in 50 relatively able children with autism
Authors:
- Marjoleine E.M. DekkerMDMarjoleine E.M. Dekker
- Jan M. van ReeJRJan M. van Ree
- Herman van EngelandHEHerman van Engeland
- 31 March 1996
- journal article
- clinical trial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 6 (1) , 13-19
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Medial temporal lobe structures and autism: A review of clinical and experimental findingsNeuropsychologia, 1994
- The Assessment of Individual Differences Between Young Children With a Pervasive Developmental Disorder by Means of Behaviour Scales Which are Derived from Direct ObservationJournal of Child Psychology and Psychiatry, 1994
- Subclassification of children with autism and pervasive developmental disorder: A questionnaire based on Wing's Subgrouping schemeJournal of Autism and Developmental Disorders, 1993
- The Adrenocorticotrophic Hormone (4–9) Analog ORG 2766 Benefits Autistic Children: Report on a Second Controlled Clinical TrialJournal of the American Academy of Child & Adolescent Psychiatry, 1992
- The use of adrenocorticotrophic hormone (4–9) analog ORG 2766 in autistic children: Effects on the organization of behaviorBiological Psychiatry, 1992
- The MSH/ACTH(4–9) analog Org2766 counteracts isolation-induced enhanced social behavior via the amygdalaPeptides, 1992
- Deficits in social behavior in autism and their modification by a synthetic adrenocorticotrophic hormone (4–9) analogCellular and Molecular Life Sciences, 1992
- Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.Journal of Consulting and Clinical Psychology, 1991
- Neuropeptides derived from pro-opiocortin: behavioral, physiological, and neurochemical effects.Physiological Reviews, 1982
- A Coefficient of Agreement for Nominal ScalesEducational and Psychological Measurement, 1960